studies

metastatic/advanced hepatocellular cancer (mHCC), pembrolizumab based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-240, 2020 0.78 [0.61; 1.00] 0.78[0.61; 1.00]KEYNOTE-240, 202010%413NAnot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-240, 2020 0.72 [0.57; 0.90] 0.72[0.57; 0.90]KEYNOTE-240, 202010%413NAnot evaluable DCRdetailed resultsKEYNOTE-240, 2020 1.44 [0.95; 2.19] 1.44[0.95; 2.19]KEYNOTE-240, 202010%413NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-240, 2020 4.83 [2.02; 11.57] 4.83[2.02; 11.57]KEYNOTE-240, 202010%413NAnot evaluable AE (any grade)detailed resultsKEYNOTE-240, 2020 2.89 [1.23; 6.77] 2.89[1.23; 6.77]KEYNOTE-240, 202010%413NAnot evaluable AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 1.26 [0.83; 1.90] 1.26[0.83; 1.90]KEYNOTE-240, 202010%413NAnot evaluable AE leading to death (grade 5)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsKEYNOTE-240, 2020 2.11 [1.08; 4.13] 2.11[1.08; 4.13]KEYNOTE-240, 202010%413NAnot evaluable AE leading to treatment discontinuation (grade 3-4)detailed resultsKEYNOTE-240, 2020 3.04 [1.32; 6.97] 3.04[1.32; 6.97]KEYNOTE-240, 202010%413NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-240, 2020 1.66 [1.09; 2.51] 1.66[1.09; 2.51]KEYNOTE-240, 202010%413NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 2.77 [1.36; 5.65] 2.77[1.36; 5.65]KEYNOTE-240, 202010%413NAnot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.24 [0.02; 2.64] 0.24[0.02; 2.64]KEYNOTE-240, 202010%413NAnot evaluable Arthralgia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 1.93 [0.09; 43.05] 1.93[0.09; 43.05]KEYNOTE-240, 202010%413NAnot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Cough TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 2.90 [0.14; 58.35] 2.90[0.14; 58.35]KEYNOTE-240, 202010%413NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.03; 7.71] 0.48[0.03; 7.71]KEYNOTE-240, 202010%413NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.09; 10.69] 0.96[0.09; 10.69]KEYNOTE-240, 202010%413NAnot evaluable Dry skin TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Dysgeusia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Dyspepsia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Eczema TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 1.45 [0.15; 14.03] 1.45[0.15; 14.03]KEYNOTE-240, 202010%413NAnot evaluable Headache TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 3.88 [0.20; 74.00] 3.88[0.20; 74.00]KEYNOTE-240, 202010%413NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 3.75 [0.85; 16.64] 3.75[0.85; 16.64]KEYNOTE-240, 202010%413NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 2.45 [0.53; 11.36] 2.45[0.53; 11.36]KEYNOTE-240, 202010%413NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.24 [0.01; 7.16] 0.24[0.01; 7.16]KEYNOTE-240, 202010%413NAnot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 1.93 [0.09; 43.05] 1.93[0.09; 43.05]KEYNOTE-240, 202010%413NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Rash TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 5.87 [0.33; 105.85] 5.87[0.33; 105.85]KEYNOTE-240, 202010%413NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 3.88 [0.20; 74.00] 3.88[0.20; 74.00]KEYNOTE-240, 202010%413NAnot evaluable Anaemia AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.42 [0.18; 0.97] 0.42[0.18; 0.97]KEYNOTE-240, 202010%413NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.03; 7.71] 0.48[0.03; 7.71]KEYNOTE-240, 202010%413NAnot evaluable Asthenia AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Back pain AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 3.88 [0.20; 74.00] 3.88[0.20; 74.00]KEYNOTE-240, 202010%413NAnot evaluable Constipation AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Cough AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 2.90 [0.14; 58.35] 2.90[0.14; 58.35]KEYNOTE-240, 202010%413NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.64 [0.14; 2.88] 0.64[0.14; 2.88]KEYNOTE-240, 202010%413NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.12 [0.01; 2.65] 0.12[0.01; 2.65]KEYNOTE-240, 202010%413NAnot evaluable Fatigue AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 1.70 [0.35; 8.29] 1.70[0.35; 8.29]KEYNOTE-240, 202010%413NAnot evaluable Increase AST AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 1.90 [0.91; 3.94] 1.90[0.91; 3.94]KEYNOTE-240, 202010%413NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 2.11 [0.70; 6.39] 2.11[0.70; 6.39]KEYNOTE-240, 202010%413NAnot evaluable Nausea AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.09; 10.69] 0.96[0.09; 10.69]KEYNOTE-240, 202010%413NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.48 [0.01; 24.29] 0.48[0.01; 24.29]KEYNOTE-240, 202010%413NAnot evaluable Pruritus AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 0.96 [0.03; 28.81] 0.96[0.03; 28.81]KEYNOTE-240, 202010%413NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 1.93 [0.09; 43.05] 1.93[0.09; 43.05]KEYNOTE-240, 202010%413NAnot evaluable Rash AE (grade 3-4)detailed resultsKEYNOTE-240, 2020 1.93 [0.09; 43.05] 1.93[0.09; 43.05]KEYNOTE-240, 202010%413NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-03 09:42 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 40,132,131,133 - treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons